Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ahead ...
Here’s all you need to know about the magic that happens inside your EV battery and how it impacts range, charging and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback